Gland Pharma Ltd
NSE:GLAND
Gland Pharma Ltd
Free Cash Flow
Gland Pharma Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gland Pharma Ltd
NSE:GLAND
|
Free Cash Flow
₹6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Free Cash Flow
₹8.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Free Cash Flow
₹29.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Free Cash Flow
₹107.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Free Cash Flow
₹29.3B
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Free Cash Flow
₹17.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gland Pharma Ltd
Glance View
Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare. What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.
See Also
What is Gland Pharma Ltd's Free Cash Flow?
Free Cash Flow
6B
INR
Based on the financial report for Mar 31, 2024, Gland Pharma Ltd's Free Cash Flow amounts to 6B INR.
What is Gland Pharma Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
65%
Over the last year, the Free Cash Flow growth was 325%. The average annual Free Cash Flow growth rates for Gland Pharma Ltd have been 17% over the past three years , 65% over the past five years .
You don't have any saved screeners yet